These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9339268)

  • 41. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease.
    Cummings JL; Schneider L; Tariot PN; Kershaw PR; Yuan W
    Am J Psychiatry; 2004 Mar; 161(3):532-8. PubMed ID: 14992980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.
    Fisher A; Heldman E; Gurwitz D; Haring R; Karton Y; Meshulam H; Pittel Z; Marciano D; Brandeis R; Sadot E; Barg Y; Pinkas-Kramarski R; Vogel Z; Ginzburg I; Treves TA; Verchovsky R; Klimowsky S; Korczyn AD
    Ann N Y Acad Sci; 1996 Jan; 777():189-96. PubMed ID: 8624083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.
    Azargoonjahromi A
    Clin Drug Investig; 2024 Jul; 44(7):471-493. PubMed ID: 38904739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effectiveness of amiridin in senile dementia of the Alzheimer type].
    Bukatina EE; Grigor'eva IV; Sokol'nik EI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(9):53-8. PubMed ID: 1664616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
    Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM
    Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Classics in Chemical Neuroscience: Xanomeline.
    Bender AM; Jones CK; Lindsley CW
    ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of phosphatidylserine in Alzheimer's disease.
    Crook T; Petrie W; Wells C; Massari DC
    Psychopharmacol Bull; 1992; 28(1):61-6. PubMed ID: 1609044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.
    Vardigan JD; Cannon CE; Puri V; Dancho M; Koser A; Wittmann M; Kuduk SD; Renger JJ; Uslaner JM
    Psychopharmacology (Berl); 2015 Jun; 232(11):1859-66. PubMed ID: 25491927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
    Breier A; Brannan SK; Paul SM; Miller AC
    Psychopharmacology (Berl); 2023 May; 240(5):1191-1198. PubMed ID: 37036495
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study.
    Gutzmann H; Hadler D
    J Neural Transm Suppl; 1998; 54():301-10. PubMed ID: 9850939
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease.
    Cummings JL
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S1-9. PubMed ID: 9339266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease.
    Cutler NR; Shrotriya RC; Sramek JJ; Veroff AE; Seifert RD; Reich LA; Hironaka DY
    Ann N Y Acad Sci; 1993 Sep; 695():332-6. PubMed ID: 8239308
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.
    Street JS; Clark WS; Kadam DL; Mitan SJ; Juliar BE; Feldman PD; Breier A
    Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S62-70. PubMed ID: 11748789
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A bridging study of LU 25-109 in patients with probable Alzheimer's disease.
    Sramek JJ; Forrest M; Mengel H; Jhee SS; Hourani J; Cutler NR
    Life Sci; 1998; 62(3):195-202. PubMed ID: 9488097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Somatostatin replacement therapy for Alzheimer dementia.
    Mouradian MM; Blin J; Giuffra M; Heuser IJ; Baronti F; Ownby J; Chase TN
    Ann Neurol; 1991 Oct; 30(4):610-3. PubMed ID: 1789687
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.
    Raskind MA; Sadowsky CH; Sigmund WR; Beitler PJ; Auster SB
    Arch Neurol; 1997 Jul; 54(7):836-40. PubMed ID: 9236571
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain.
    Montani C; Canella C; Schwarz AJ; Li J; Gilmour G; Galbusera A; Wafford K; Gutierrez-Barragan D; McCarthy A; Shaw D; Knitowski K; McKinzie D; Gozzi A; Felder C
    Neuropsychopharmacology; 2021 May; 46(6):1194-1206. PubMed ID: 33342996
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
    Kennedy JS; Zagar A; Bymaster F; Nomikos G; Trzepacz PT; Gilmore JA; Rotelli MD; Breier A; Tollefson G
    Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S24-32. PubMed ID: 11748787
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation.
    Rosas-Ballina M; Valdés-Ferrer SI; Dancho ME; Ochani M; Katz D; Cheng KF; Olofsson PS; Chavan SS; Al-Abed Y; Tracey KJ; Pavlov VA
    Brain Behav Immun; 2015 Feb; 44():19-27. PubMed ID: 25063706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Chemotherapy in Alzheimer's disease. Retrospective study in a specialized hospital center].
    Andrieu MC; Allegre G; Poisson N; Pointis P; Gekiere F; Gayral P
    Encephale; 1994; 20(4):437-44. PubMed ID: 7988408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.